The tech startup Graph AI, which specializes in the pharmaceutical industry, has successfully raised $13.3 million in a Series A funding round. The round was led by Insight Partners, with participation from existing investors, including Bessemer Venture Partners.
The funds raised will be used to expand the company's operations in the US and Europe, as well as to accelerate product development.
Graph AI was founded in 2024 by experienced employees from corporate technology companies who previously worked at organizations such as Google, Wipro, Infosys, LTI, and ServiceNow. The startup has developed an artificial intelligence platform that automates processes related to pharmacovigilance and patient safety.
Raghav Parvatiraju, CEO of Graph AI, noted that traditionally, pharmacovigilance scaled up by increasing staff and processes around outdated systems. He stated: 'We believe that intelligence can change this. Graph Safety provides safety experts with an intelligent system that takes on operational complexity while keeping traceability, accountability, and human oversight central.'
The startup's platform combines artificial intelligence with deterministic controls, validation levels, and end-to-end audit trails specifically designed for regulated pharmacovigilance environments. The platform's development took into account applicable regulatory requirements and evolving expectations regarding the use of AI in drug development and patient safety.
Graph AI claims that during real-world implementation, its platform reduced case processing time from over three hours to less than ten minutes, allowing for a reduction in operating costs by up to 66%.
The company has already attracted clients from the pharmaceutical and biotechnology sectors in North America and other markets, and has also signed partnership agreements for module development.
Richard Mattus, Senior Partner at Insight Partners, commented on the situation, noting that pharmaceutical companies must ensure absolute patient safety, but most are unwilling to integrate disparate tools to achieve this goal. He added that software and service providers are not keeping pace with what modern AI is capable of doing to increase accuracy and value for pharma companies.